Patents by Inventor Rémy Gébleux

Rémy Gébleux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOCATALYTICAL COMPOSITION AND USE FOR GENERATION OF IMMUNOLIGAND-PAYLOAD CONJUGATES
    Publication number: 20240158435
    Abstract: The present invention relates to a composition comprising a solid carrier, a capture moiety, a functional protein, a first linker connecting the capture moiety to the solid carrier, a second linker connecting the functional protein to the capture moiety, a first protective layer fully embedding the solid carrier, fully or partially embedding the first linker, and not or partially embedding the capture moiety, a second protective layer fully or partially embedding the capture moiety, fully embedding the second linker, and fully or partially embedding the functional protein.
    Type: Application
    Filed: March 17, 2022
    Publication date: May 16, 2024
    Inventors: Patrick SHAHGALDIAN, Manon BRIAND, Philippe F.-X. CORVINI, Maria Rita CORRERO, Yves DUDAL, Ulf GRAWUNDER, Rémy GEBLEUX, Roger R. BEERLI
  • Non-glycosylated anti-tenascin antibody
    Patent number: 10906963
    Abstract: The present invention relates to variants of the anti-tenascin antibody F16 which are modified to abolish N-glycosylation at positions 88 to 90 in the VL domain. This results in dramatically improved properties, such as improved binding affinity and tumour biodistribution in vivo. Variant F16 antibody molecules and methods for their production and use are provided.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: February 2, 2021
    Assignee: Philogen S.P.A
    Inventors: Rémy Gébleux, Sarah Wulhfard
  • Non-Glycosylated Anti-Tenascin Antibody
    Publication number: 20190127451
    Abstract: The present invention relates to variants of the anti-tenascin antibody F16 which are modified to abolish N-glycosylation at positions 88 to 90 in the VL domain. This results in dramatically improved properties, such as improved binding affinity and tumour biodistribution in vivo. Variant F16 antibody molecules and methods for their production and use are provided.
    Type: Application
    Filed: April 12, 2017
    Publication date: May 2, 2019
    Inventors: Rémy Gébleux, Sarah Wulhfard